Nature Medicine, Published online: 06 January 2025; doi:10.1038/s41591-024-03360-5
In a multicenter, open-label, randomized phase 2 trial, neoadjuvant chemoradiation with PD-1 blockade elicited a pathological complete response rate superior to that with neoadjuvant chemoradiation alone in patients with locally advanced rectal cancer.
